2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Thursday, March 30, 2023

6:00PM-7:00PM: Abstract Number: 041

Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 046

Colchicine Adherence Among Children and Young Adults with Familial Mediterranean Fever During Treatment with interleukin-1 Inhibitors

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 048

Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 055

COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 076

COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 054

Craniofacial Localized Scleroderma: A Single Center Retrospective Cohort

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 087

Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic

Posters: Quality, Health Services, and Education I

6:00PM-7:00PM: Abstract Number: 043

Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 079

Dynamics of Neutrophil Activation in Repeated TLR-9-Induced Mouse Model of Macrophage Activation Syndrome

Posters: Genetics and Pathogenesis I

6:00PM-7:00PM: Abstract Number: 075

Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 052

Extreme Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA): A Discrete Group of Patients

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 082

Globalization and Real-World Implementation of an International Pediatric Rheumatology Learning Resource

Posters: Quality, Health Services, and Education I

6:00PM-7:00PM: Abstract Number: 073

Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 058

High Levels of Psychological Distress, Depression, and Anxiety Symptoms in Children with Pediatric Rheumatologic Diseases

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 085

Identification of Barriers to Care Experienced by Children with Rheumatic Disease: A Qualitative Study

Posters: Quality, Health Services, and Education I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].